Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Total Current Liabilities: 2010-2024

Historic Total Current Liabilities for Iovance Biotherapeutics (IOVA) over the last 10 years, with Dec 2024 value amounting to $122.3 million.

  • Iovance Biotherapeutics' Total Current Liabilities was N/A to $125.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $125.8 million, marking a year-over-year change of. This contributed to the annual value of $122.3 million for FY2024, which is 10.91% up from last year.
  • Iovance Biotherapeutics' Total Current Liabilities amounted to $122.3 million in FY2024, which was up 10.91% from $110.3 million recorded in FY2023.
  • In the past 5 years, Iovance Biotherapeutics' Total Current Liabilities ranged from a high of $122.3 million in FY2024 and a low of $110.3 million during FY2023.
  • Over the past 2 years, Iovance Biotherapeutics' median Total Current Liabilities value was $116.3 million (recorded in 2023), while the average stood at $116.3 million.
  • Data for Iovance Biotherapeutics' Total Current Liabilities shows a peak YoY increased of 10.91% (in 2024) over the last 5 years.
  • Over the past 2 years, Iovance Biotherapeutics' Total Current Liabilities (Yearly) stood at $110.3 million in 2023, then increased by 10.91% to $122.3 million in 2024.